Vlaams Instituut voor Biotechnologie (VIB) Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03784066
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Vlaams Instituut Biotechnologie (VIB) | Vlaams Instituut voor Biotechnologie (VIB)

Active Ingredients

Drugs in Phase 3 Trials (1)

rosuvastatin (crestor) (1 trial)

Drugs in Phase 2 Trials (2)

durvalumab (imfinzi) (1 trial)

tremelimumab (Imjudo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3